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a b s t r a c t 
Neuraminidase (NA) is a surface glycoprotein produced by the inﬂuenza virus. Speciﬁc NA mutations 
that confer resistance to anti-viral drugs have been reported. The aim of this study was to demonstrate 
quick preparation of the mutated NAs using the yeast surface display and its applicability for screening 
inhibitors. Plasmids encoding the head domain of wild-type and drug-resistant NAs were constructed 
and introduced into yeast, and these were successfully displayed on the yeast surface, with biochemical 
properties similar to the native virus NAs. This system using mutated NAs-displaying yeast provides an 
efﬁcient and convenient tool for screening novel inhibitors against the drug-resistant inﬂuenza virus. 
C © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical 
Societies. Open access under CC BY-NC-ND license.. Introduction 
Human seasonal inﬂuenza is responsible for an estimated 
50,000–500,000 deaths and 3–5 million cases of severe illness annu- 
lly worldwide [ 1 ]. Recently, the novel swine-origin virus (Inﬂuenza 
 H1N1 2009), which emerged potentially through the reassort- 
ent of triple North American H3N2 and H1N2 swine viruses with 
urasian avian-like swine viruses [ 2 ], entered the human population 
nd spread rapidly around the globe, prompting the WHO to declare 
 pandemic in 2009 [ 3 ]. In addition, the highly pathogenic avian in- 
uenza A virus H5N1 has been sporadically epidemic since 1997 with 
 high mortality rate of 60% in humans and poses a serious pandemic 
hreat [ 4 ]. 
Neuraminidase (NA) is a viral surface glycoprotein that plays a 
rucial role in the release of the newly formed virus from the infected 
ells, and has been the main target of current inﬂuenza antiviral treat- 
ent. Oseltamivir, one of the ﬁrst-developed NA inhibitors has been 
ost widely used for the treatment of patients with inﬂuenza virus 
nfection. However, an oseltamivir-resistant H1N1 virus that harbors 
 speciﬁc mutation (H274Y) in the NA protein has been recently re- 
orted [ 5 ] as has been, to a lesser extent, the emergence of the avian Abbreviations: NA, neuraminidase; HNA, head domain of neuraminidase. 
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ttp://dx.doi.org/10.1016/j.fob.2013.10.007 inﬂuenza H5N1 virus with the same mutation [ 6 ]. These facts raise 
public health concerns and therefore there is a need to develop a 
novel, efﬁcient, and a rapid screening system for the identiﬁcation of 
novel inhibitors. 
One of the ﬁrst steps in drug discovery is the preparation of the 
target protein, which requires laborious processes including not only 
protein production and conﬁrmation of activity but also puriﬁcation, 
a most time-consuming process. As to inﬂuenza virus NAs, although 
their biotechnological production was achieved by the secretory sys- 
tem using insect, yeast, and mammalian cells for the head domain of 
NA, all the researchers will need several steps to purify it [ 7 –9 ]. In 
this regard, the yeast cell surface display technology is promising; it 
has been used for screening binding proteins with speciﬁc afﬁnity to 
a target molecule and endowing yeasts with heterogenous abilities 
like glucoamylase activity [ 10 , 11 ]. In this system, a heterologous pro- 
tein of interest can be displayed on the yeast cell surface as a fusion 
protein with agglutinins, a cell wall protein that is involved in mating. 
In fact, the yeast cell surface display system has been used in various 
ﬁelds such as bioconversion, antibody engineering, and the devel- 
opment of bio-adsorbents [ 12 –17 ]. Besides versatile applications as 
described above, the cumbersome steps involved in the puriﬁcation of 
the recombinant proteins are avoided by using the yeast cell surface 
display system. Further, owing to the ease of gene manipulation, the 
fast growth in a low-cost medium, and the existence of the quality 
control system of endogenous protein production in the endoplas- 
mic reticulum, though it is not special to yeast, we can easily prepare 
yeasts displaying mutated proteins of interest through construction 
of plasmids with mutations in the target protein-coding DNA ( Fig. 1 ). ean Biochemical Societies.  Open access under CC BY-NC-ND license.
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Fig. 1. An illustration of the steps involved in use of yeast cell surface display system to produce the enzymes of interest. Once the original NA-displaying yeast cells are successfully 
constructed, it will take only within 3–4 days, including transformation and incubation, to obtain yeast cells displaying mutated NAs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Here, we constructed yeasts displaying the head domain of wild-
type or oseltamivir-resistant NAs. Then, we evaluated the biochemical
properties such as NA enzymatic activities at different cultivation
times, sensitivity to NA inhibitors, and thermal stability of the cell
surface-displayed NAs. 
2. Materials and methods 
2.1. Strains and media 
Escherichia coli DH5 α(F −, Δlac U169 ( ϕ 80d lac Z M15), hsd R17 ( r K −,
m K 
+ ), rec A1, end A1, deo R, thi -1, sup E44, gyr A96, rel A1, λ−) (TOYOBO,
Osaka, Japan) was used as a host for DNA manipulation. Saccharomyces
cerevisiae BY4742 ( MAT α, his3–1 , leu2 , lys2 , ura3 ; EUROSCARF, Frank-
furt, Germany) was used to construct yeasts displaying NAs. E. coli
transformants were grown at 37 ◦C in Luria–Bertani media (1% ( w /
v ) tryptone, 0.5% ( w / v ) yeast extract, and 1% ( w / v ) sodium chloride)
containing 100 μg / mL ampicillin. Yeast transformants were selected
on a synthetic dextrose (SDC) solid medium (0.67% ( w / v ) yeast nitro-
gen base without amino acids, 2% ( w / v ) glucose, 1% ( w / v ) casamino
acids, 0.002% ( w / v ) adenine, 0.002% ( w / v ) l -tryptophan, and 2% ( w / v )
agar), and then, the resultant colonies were aerobically cultivated at
30 ◦C in a liquid SDC medium (pH 6.5) supplemented with 100 mM
2-morpholinoethanesulfonic acid (MES). 
2.2. Vectors for expression 
The DNA fragment encoding head domain of neu-
raminidase (HNA, 387 amino acids in length) was PCR-
ampliﬁed from the pTZ-NA plasmid that harbors the neu-
raminidase gene from the Fujian H5N1 virus, using sense [5 ′ -
CTTACTTTTCTTTGCTCGTTTCTGCCGTAACATTAGCGGGCAATTCATCTC-
3 ′ ], antisense [5 ′ -CATCCTTGTAATCAGATCCACCCTCGAGCTTGTCAAT
GGTGAATGGCAAC-3 ′ ] primers, and the KOD-Plus-Neo DNA poly-
merase (TOYOBO) ( Fig. 2 A). The DNA fragment was inserted into
Bgl II / Xho I-digested pULD1, which codes for the C-terminal half
of α-agglutinin downstream of the multiple cloning sites, using
In-Fusion HD Cloning kit (Clontech, Mountain view, CA, USA).
The resultant plasmid is referred to as pULD1-HNA / WT. The
plasmid encoding the head domain of oseltamivir-resistant NA(H274Y) was constructed by mutating pULD1-HNA / WT using the
primers 5 ′ -GAATGCTCCTAATTAT T ACTATGAGGAATGCTCC-3 ′ and
5 ′ -GGAGCATTCCTCATAGT A ATAATTAGGAGCATTC-3 ′ (the under-
lines indicates mutation points) and the QuikChange Site-Directed
Mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA), and
the plasmid was termed pULD1-HNA / H274Y. pULD1-Strep, which
encodes a Strep-tag instead of a FLAG-tag, was constructed as the
negative control plasmid for immunoﬂuorescence staining. 
2.3. Transformation of yeast 
Yeasts were transformed using the Frozen-EZ Yeast
Transformation-II kit (Zymo Research, Irvine, CA, USA). After
the introduction of plasmids, the yeast transformants were selected
on a uracil-deﬁcient SDC solid medium. 
2.4. Neuraminidase activity assay 
Yeast transformants were pre-cultivated in a buffered SDC
medium for 36 h, and then the main cultivation was initiated at an
initial optical density (OD) of 0.1 at 600 nm in 10 mL of buffered SDC
medium. At the indicated times of cultivation, the yeast cells were
collected and suspended in the NA assay buffer containing 5 mM
CaCl 2 and 50 mM MES pH 6.5. The yeast suspension (50 μL) contain-
ing 10 7 cells was transferred onto a 96-well microplate (353072; BD
Biosciences, CA, USA) and mixed with 50 μL of the NA assay buffer con-
taining 100 μM 4-methylumbelliferyl- N -acetyl- α- d -neuraminic acid
(MUNANA) (Sigma–Aldrich, St.Louis, MO, USA) as a ﬂuorogenic sub-
strate. After incubation for 15 min at 37 ◦C, 250 mM glycine pH 10.4
was added to stop the reaction and then the ﬂuorescence was mea-
sured with a Fluoroskan Ascent Fluorometer (Labsystems, Helsinki,
Finland) with an excitation at 355 nm and an emission at 460 nm. For
the inhibition assay, 2 types of NA inhibitors, oseltamivir carboxylate
(Shanghai Haoyuan Chemexpress, Shanghai, China) and zanamivir
(LKT Laboratories, St. Paul, MN, USA), were used. 
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Fig. 2. (A) Sequence of head domain of neuraminidase (HNA). The gray color shows the sequence of the HNA. The box indicates FLAG tag. (B) Plasmid constructed for yeast surface 
display of the HNA. Head, head domain. (B) A microscopic observation of surface display after immunoﬂuorescence staining. Forty-eight hours after cultivation of the yeast, the 
display of NAs on yeast was examined by immunoﬂuorescence staining using an anti-FLAG M2 mouse IgG antibody followed by an Alexa Flour 488-conjugated anti-mouse IgG 
antibody. The yeast suspension was transferred onto a glass slide and observed under a ﬂuorescence microscope. Scale bars indicate 5 μm. 
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c.5. Microscopic observation and determination of the HNA display 
fﬁciency 
Yeasts were collected at 10 7 cells per tube in a 1.5 mL microtube 
nd washed once with 1 mL of phosphate-buffered saline (PBS) pH 
.4. The pellets after centrifugation were suspended in PBS contain- 
ng 0.5% ( w / v ) bovine serum albumin and 2.5 μg / mL anti-FLAG M2 
ouse IgG antibody (Sigma–Aldrich) and incubated for 1 h with rota- 
ion. After washing with PBS, the pellets were suspended in PBS con- 
aining 0.5% ( w / v ) bovine serum albumin and 5 μg / mL Alexa Flour 
88-conjugated anti-mouse IgG antibody (Invitrogen, Carlsbad, CA, 
SA) and incubated for 1 h with rotation. After washing twice with 
BS, the pellets were suspended in 300 μL of PBS and transferred onto 
 glass slide for ﬂuorescence microscopic observation. To determine 
he display efﬁciency, 250 μL of the cell suspension was transferred 
nto a 96-well microplate, and the ﬂuorescence was measured with a 
luoroskan Ascent Fluorometer, with an excitation at 485 nm and an 
mission at 537 nm [ 17 ]. 
.6. Evaluation of thermal stability 
Yeast displaying HNA / WT was suspended in NA assay buffer at the 
oncentration of 2 × 10 8 cells / mL and incubated at 37 ◦C for 72 h, 
nd the enzyme activity was assayed by the same method described 
bove. The activity was indicated as a percentage, with the activity of 
ontrol sample incubated at 4 ◦C for 72 h considered to be 100%. 3. Results 
3.1. Conﬁrmation of HNA display on yeast surface 
To display the head domain of Fujian H5N1 virus-derived NA 
(HNA), we constructed expression plasmid, pULD1-HNA / WT ( Fig. 2 B) 
and introduced it into S. cerevisiae BY4742. After the cultivation, we 
detected the displayed NAs on the yeast cell surface by ﬂuorescence 
immunostaining (Fig. 2C). These results indicated that HNA was suc- 
cessfully displayed on the yeast surface. 
3.2. Enzyme activity and display efﬁciency of HNAs on the yeast cell 
surface 
We next examined the enzymatic activity of the displayed HNAs 
(both the wild-type and the mutant) by using a ﬂuorogenic substrate 
under the condition without an interfering effect of yeasts on the 
ﬂuorescence intensity ( Supplementary Fig. 1 ). The HNA mutant with 
H274Y substitution (HNA / H274Y) was chosen because this mutant 
is resistant to oseltamivir, one of the most widely used drugs for the 
treatment of inﬂuenza infection in humans. The mechanism by which 
the HNA / H274Y has resistance to oseltamivir is the interference of its 
access to the active site owing to a pentoxyl group at position 3 in 
oseltamivir, whose functional group does not exist in zanamivir [ 18 ]. 
We evaluated the NA enzymatic activity of the yeast transformants 
displaying HNA / WT and HNA / H274Y at different cultivation times. 
When HNA / WT was displayed on the yeast surface, the NA activity 
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Fig. 3. Time course of the enzyme activity (A) and display efﬁciency (B) for HNA / WT and HNA / H274Y. The enzyme activity is represented in relative ﬂuorescence units (RFU) 
divided by OD 600 . The display efﬁciency was determined by immunoﬂuorescence staining and measurement of the ﬂuorescence intensity by Fluoroskan Ascent Fluorometer with 
an excitation at 485 nm and an emission at 537 nm. The data were expressed as percent of RFU in which the value of HNA / WT-displaying yeast at 96 h was 100%. The data represent 
the average of 3 independent experiments, and the error bars depict the SEM. * p < 0.05, determined by two-way ANOVA. 
Fig. 4. Concentration–response curve on HNAs displayed on yeast with increasing dose of inhibitors, oseltamivir carboxylate (left) and zanamivir (right). HNA / WT or HNA / H274Y 
displayed on the yeast cell surface was subjected to an inhibition assay by the addition of the indicated concentrations of the inhibitors. The enzyme activity without any inhibitors 
was represented as 100%, and IC 50 values were calculated based on the inhibition curves. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 was signiﬁcant at 24 h (79.7 ± 4.5 RFU / OD 600 ), with the peak being
observed at 72 h (153.5 ± 16.5 RFU / OD 600 ). A similar trend was
also observed in yeasts displaying HNA / H274Y, although the enzyme
activity level was 1.5- to 2.4-fold lower than that observed in the
HNA / WT-displaying yeasts at the all time points examined ( Fig. 3 A),
and this difference in enzyme activity was statistically signiﬁcant
( p < 0.05). The control yeast without HNAs on the surface showed no
enzyme activity at all the cultivation times tested. 
In order to conﬁrm that the difference in the enzyme activity ob-
served is due to the H274Y substitution in the HNA, we determined
the display efﬁciencies of both HNAs on yeast surface by immunoﬂu-
orescence staining. As seen in Fig. 3 B, the display efﬁciencies of HNA /
WT and HNA / H274Y on the yeast surface were not different. These
results demonstrated that the H274Y mutation does not alter the dis-
play efﬁciency, but lowers the enzyme activity ( Fig. 3 A). In support of
this conclusion, the previous study by Collins et al. [ 18 ] reported that
the Michaelis constant for the enzyme carrying the H274Y mutation
increased when compared to that of the wild-type enzyme. 
For the inﬂuence of the C-terminal FLAG tag on enzyme activity,
the yeast with the FLAG tag-free NA showed 1.4-fold higher activ-
ity than that with the NA possessing FLAG tag at the C-terminus
( Supplementary Fig. 2 ). 3.3. Inhibition of the displayed HNAs on yeast by NA inhibitors 
Both HNA / WT and HNA / H274Y showed signiﬁcant enzymatic ac-
tivity and we examined the effect of 2 types of selective NA inhibitors
on this activity. Oseltamivir carboxylate (the active ingredient of Tam-
iﬂu) and zanamivir (the active ingredient of Relenza) were used as in-
hibitors. When we conducted a test for concentration-response curve
on the HNA / WT on yeast, the IC 50 was 9.1 and 8.8 nM for oseltamivir
carboxylate and zanamivir, respectively ( Fig. 4 ). On the other hand,
while zanamivir showed the near or higher inhibition activity on the
HNA / H274Y whose IC 50 was 4.1 nM, oseltamivir carboxylate was
only able to inhibit the activity by 28% even at 160 nM, the highest
concentration in this test. This inhibition properties and IC 50 values
of oseltamivir carboxylate and zanamivir on the HNA / WT and the
HNA / H274Y were consistent with the previous reports in which NA
derived from inﬂuenza virus grown in hen eggs or MDCK cells was
used for carrying out inhibition study [ 18 , 19 ]. Thus, we conclude that
the HNAs displayed on the yeast surface have the same property as
the native and mutated NAs present on the virus surface. 
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Fig. 5. Thermal stability of displayed HNA / WT. Yeast displaying HNA / WT was sus- 
pended in NA assay buffer at the concentration of 2 × 10 8 cells / mL and incubated at 
37 ◦C for 72 h, and the enzyme activity was assayed. The data represent the average 
of 3 independent experiments, and the error bars depict the SEM. n.s. indicates not 
signiﬁcant. 
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h.4. Thermal stability 
When enzymes (including NAs) are used to screen for inhibitors, 
he thermal stability of the displayed proteins during the enzyme 
eaction is important in evaluating the inhibitors. For example, cer- 
ain newly acquired mutations in enzymes of interest have been re- 
orted to give rise to drug-resistance and lowered stability simulta- 
eously, which impairs an effective screening. Speciﬁcally, McKimm- 
reschkin et al. [ 20 ] reported such mutant NAs that simultaneously 
isplayed drug-resistance and reduced thermal stability. Therefore, 
e examined the effect of heat treatment on the enzyme activity of 
he HNAs displayed on the yeast surface. The HNA displayed on the 
east surface retained their activity even after prolonged heating ( Fig. 
 ). In contrast, recombinant NA produced in insect cells is less stable 
nd is inactivated upon heat treatment [ 19 ]. These ﬁndings suggest 
hat the thermal stability of the NA displayed on the yeast cell surface 
s superior to that of the soluble NA produced in insect cells. 
. Discussion 
In the present study, we successfully produced the head domain of 
he NA from inﬂuenza H5N1 virus on the yeast cell surface. The recom- 
inant enzyme showed sufﬁcient enzyme activity and high thermal 
tability. Importantly, the available small inhibitors were able to rea- 
onably inhibit the activity of these enzymes displayed on the yeast 
urface. The successful heterologous production of the head domain 
f NA from avian inﬂuenza virus H5N1 was ﬁrst reported using the 
ethylotropic yeast Pichia pastris [ 9 ]. However, the recombinant NA 
as produced as a secreted, soluble protein which requires several 
teps for puriﬁcation. On the other hand, it should be noted that in 
he present study, the yeast displaying the HNA on the cell surface 
nly requires to be centrifuged and does not require any further pu- 
iﬁcation prior to examination of the enzyme activity. This makes the 
east surface display system very effective, especially in studying the 
pplication of enzymes (mutated and non-mutated) and screening 
or novel enzyme inhibitors. 
NA is a mushroom-shaped tetramer of identical subunits, with the 
ead of the mushroom suspended from the virus membrane. Each of the subunits that form the head of the mushroom is made up of a six- 
bladed propeller-like structure [ 21 ]. Although it is unclear whether 
the HNAs displayed on the yeast surface have a proper folding or 
tetramer structure, the proper folding of HNAs on the yeast surface 
will be partly supported by the fact that the HNA / WT or HNA / H274Y 
showed reasonable enzyme activities and inhibition properties by NA 
inhibitors. The same is true on a proper tetramerization of NA, but we 
think that it is not critical for application to drug screening because 
NA inhibitors attack the active site of NA monomer not tetramer. 
Because Schmidt et al. [ 19 ] indicated that the NA bound to the 
virus surface was highly stable during incubation at 37 ◦C compared 
with the soluble NA produced in insect cells, we considered that the 
reduced ﬂexibility of NA by being ﬁxed on the virus surface might be 
one of the factors contributing to thermal stabilization. Yeast surface 
display system is also expected to have the same stabilizing effect as 
virus, but whether the intrinsically instable NA with E119G mutation 
reported by McKimm-Breschkin et al. [ 20 ] is stabilized as well should 
be investigated for further research. 
In general, exogenous proteins produced in yeast are known to 
get high mannose type glycosylation, potentially deteriorating in- 
nate properties of target proteins. One of the examples is the sol- 
uble NA produced in P. pastris , which showed a larger molecular 
weight due to hyperglycosylation [ 9 ]. On the other hand, when HNA 
was intracellularly produced in S. cerevisiae , we detected the main 
band around 44 kDa probably showing the HNA in western blotting 
( Supplementary Fig. 3 ). In addition, the yeast without HNA on the 
surface showed a band at 102 kDa indicating α-agglutinin only, and 
the yeast displaying HNA showed a band that is 44 kDa higher than 
the α-agglutinin. These results suggest that the HNA produced in S. 
cerevisiae is likely not to have hyperglycosylation, unlike the HNA 
produced in P. pastris. 
In addition to application in enzyme assays, the yeast displaying 
HNA could be utilized for yeast-based vaccines that could be admin- 
istered subcutaneously as a whole yeast [ 22 ]. Although yeast which 
produces target antigens intracellularly has been investigated, yeast 
with desired antigens on the cell surface might be more effective be- 
cause of accessibility to immune cells. The in vivo efﬁcacy of soluble 
neuraminidase as vaccines has been demonstrated in mice challenged 
with recombinant N2 neuraminidase [ 7 ], and therefore, a prophylactic 
effect of the HNA-displaying yeast constructed here can be expected 
[ 23 ]. 
In conclusion, this system to display HNA on the yeast surface 
can be applied for screening chemical libraries in order to obtain 
inhibitors of NAs carrying various novel mutations. As it is less time 
consuming, this technique can also be applied for quick preparation 
of recombinant protein antigens from frequently mutating viruses. 
Supplementary material 
Supplementary material associated with this article can be found, 
in the online version, at doi:10.1016 / j.fob.2013.10.007 . 
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